Talquetamab Regimens Boost Survival in Multiple Myeloma
The trial found 24-month progression-free survival reached 81.3% with talquetamab, daratumumab and pomalidomide, versus 51.2% with standard care.
- On Friday, June 12, 2026, Johnson & Johnson announced positive Phase 3 MonumenTAL-3 results showing that TALVEY combined with DARZALEX FASPRO with or without pomalidomide significantly reduced disease progression or death risk in multiple myeloma patients.
- The MonumenTAL-3 trial represents the first Phase 3 study to demonstrate superior progression-free survival with a GPRC5D bispecific antibody combination in earlier-line multiple myeloma, advancing treatment options earlier in the disease journey.
- At 24 months, progression-free survival reached up to 81.3% and overall survival reached up to 89.2%, with Tal-DP demonstrating a 72% reduction in disease progression or death risk versus standard regimens.
- Dr. Peter Voorhees, Professor of Hematology and Oncology at Wake Forest University School of Medicine, said the results point to "the promise of TALVEY plus DARZALEX FASPRO" as a new treatment option for relapsed or refractory multiple myeloma.
- Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA and a Type II variation application to the European Medicines Agency to bring these treatment combinations to eligible patients globally.
14 Articles
14 Articles
The Laconia Daily Sun
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and…
Talquetamab Regimens Boost Survival in Multiple Myeloma
(MedPage Today) -- Talquetamab (Talvey) plus daratumumab (Darzalex) with or without pomalidomide (Pomalyst) significantly improved survival outcomes over an active regimen for relapsed or refractory multiple myeloma, a phase III trial showed....
J&J Stock Trades Near Highs With Talvey Data Bringing Pipeline Into View
Beazley traded flat at 1,283p, just below Zurich’s 1,310p-a-share cash takeover offer, after Zurich disclosed further share purchases raising its stake to 4.67%; with court sanction and final approvals pending for the deal’s completion in H2 2026, the stock now reflects a narrow merger-arbitrage spread of about 2.1%, capping upside unless offer terms change. The post J&J Stock Trades Near Highs With Talvey Data Bringing Pipeline Into View appear…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
